#1 Clinical Trials Search in Europe

Sotatercept

Sotatercept is an investigational drug that has shown promise in clinical trials for treating various conditions, particularly pulmonary arterial hypertension (PAH). This article summarizes key information from multiple clinical trials evaluating sotatercept’s safety, efficacy, and potential applications in PAH and other disorders like anemia and thalassemia. The trials examine sotatercept’s effects on important outcomes in PAH patients, including exercise capacity, disease progression, and quality of life.

Table of Contents

What is Sotatercept?

Sotatercept is an innovative medication being studied for the treatment of various blood disorders and lung conditions. It is also known by other names such as ACE-011, ActRIIA-IgG1Fc, and MK-7962[1][2]. Sotatercept is a recombinant fusion protein, which means it’s a specially engineered protein made by combining parts of different proteins. In this case, it consists of a part of a human protein called activin receptor type IIA, linked to a piece of a human antibody[3].

What Conditions Does Sotatercept Treat?

Sotatercept is being investigated as a potential treatment for several conditions, including:

  • Pulmonary Arterial Hypertension (PAH): A serious lung condition where the blood pressure in the arteries of the lungs is too high, making it harder for the heart to pump blood through the lungs[4][2].
  • Beta-Thalassemia: An inherited blood disorder that reduces the production of hemoglobin, the protein in red blood cells that carries oxygen[5].
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[1].
  • Diamond Blackfan Anemia: A rare blood disorder where the bone marrow fails to produce enough red blood cells[6].
  • Chemotherapy-Induced Anemia: A common side effect in cancer patients undergoing chemotherapy[7].

How Does Sotatercept Work?

Sotatercept works by targeting a specific pathway in the body called the BMPR2/TGF-β pathway. This pathway is involved in regulating the growth and function of blood vessels and blood cells. In conditions like PAH, this pathway becomes unbalanced, leading to problems. Sotatercept helps to restore balance to this pathway, which can potentially improve symptoms and slow disease progression[4].

In blood disorders, Sotatercept is believed to stimulate the production of red blood cells, which can help improve anemia (a condition where there aren’t enough healthy red blood cells to carry oxygen throughout the body)[1][6].

How is Sotatercept Administered?

Sotatercept is typically given as a subcutaneous injection, which means it’s injected just under the skin. The dosage and frequency can vary depending on the condition being treated and the specific clinical trial. In most studies, it’s administered every 21 to 28 days[5][3].

Sotatercept in Clinical Trials

Sotatercept is currently being studied in various clinical trials for different conditions:

  • Pulmonary Arterial Hypertension (PAH): Several large Phase 3 trials are ongoing to evaluate Sotatercept’s effectiveness in treating PAH. These studies are looking at how Sotatercept affects things like exercise capacity (measured by how far patients can walk in 6 minutes), time to clinical worsening, and overall survival in PAH patients[3][8].
  • Beta-Thalassemia: A study is investigating whether Sotatercept can reduce the need for blood transfusions in patients with beta-thalassemia[5].
  • Myelodysplastic Syndromes (MDS): Research is being conducted to see if Sotatercept can improve anemia in patients with low- or intermediate-risk MDS[1].
  • Diamond Blackfan Anemia: A trial is exploring whether Sotatercept can reduce or eliminate the need for blood transfusions in patients with this rare condition[6].
  • Chemotherapy-Induced Anemia: Studies have looked at Sotatercept’s potential to treat anemia in cancer patients undergoing chemotherapy[7].

Potential Side Effects

As with any medication, Sotatercept may cause side effects. Common side effects reported in clinical trials include:

  • Increased blood pressure
  • Changes in hemoglobin levels
  • Headache
  • Dizziness
  • Fatigue

It’s important to note that side effects can vary depending on the condition being treated and the dosage used. In clinical trials, researchers carefully monitor participants for any adverse events to ensure patient safety[8][7].

Future Research and Potential

Sotatercept shows promise in treating a variety of conditions, particularly those involving blood disorders and lung function. Ongoing research is exploring its potential in different patient populations, including children with PAH[9]. As more clinical trial results become available, we’ll gain a better understanding of Sotatercept’s effectiveness and safety profile.

It’s important to remember that while Sotatercept shows promise, it is still an investigational drug. This means it hasn’t yet been approved by regulatory agencies like the FDA for widespread use. Patients interested in Sotatercept should discuss current treatment options and potential clinical trial participation with their healthcare providers.

Aspect Details
Drug Name Sotatercept (also known as ACE-011, MK-7962)
Primary Conditions Studied Pulmonary Arterial Hypertension (PAH), Anemia in Myelodysplastic Syndromes, Beta-Thalassemia
Mechanism of Action Activin receptor type IIA ligand trap, targeting BMPR2/TGF-β pathway
Administration Subcutaneous injection every 3 weeks, typical starting dose 0.3 mg/kg, target dose 0.7 mg/kg
Key Outcome Measures 6-minute walk distance, WHO functional class, NT-proBNP levels, hemodynamic parameters, quality of life, time to clinical worsening
Safety Monitoring Hemoglobin levels, blood pressure, platelet counts, adverse events
Patient Populations Adults with PAH (including newly diagnosed and high-risk patients), children with PAH, patients with anemia or thalassemia
Trial Phases Phase 2, Phase 3, and Phase 4 studies

FAQ

  • What is sotatercept and how does it work? Sotatercept is a recombinant fusion protein that acts as an activin receptor type IIA ligand trap. It works by targeting the BMPR2/TGF-β pathway to restore balance between pro- and anti-proliferative factors in the pulmonary vasculature. This helps counteract vascular remodeling in conditions like pulmonary arterial hypertension.
  • What conditions is sotatercept being studied to treat? Sotatercept is primarily being studied as a treatment for pulmonary arterial hypertension (PAH). It is also being investigated for potential use in other conditions like anemia associated with myelodysplastic syndromes, beta-thalassemia, and Diamond Blackfan anemia.
  • What are some key outcomes being measured in sotatercept clinical trials for PAH? Key outcomes measured in PAH trials include 6-minute walk distance, WHO functional class, NT-proBNP levels, hemodynamic parameters like mean pulmonary artery pressure and pulmonary vascular resistance, quality of life measures, and time to clinical worsening events like hospitalization or death.
  • How is sotatercept administered in clinical trials? In most trials, sotatercept is administered as a subcutaneous injection every 3 weeks. The typical starting dose is 0.3 mg/kg, with a target dose of 0.7 mg/kg in many studies. Dose adjustments may be made based on individual patient response and tolerability.
  • What are some potential side effects of sotatercept being monitored? Potential side effects being monitored include changes in hemoglobin levels, blood pressure, and platelet counts. Researchers are also tracking any adverse events that may be related to the drug, particularly those that could lead to treatment discontinuation. The overall safety and tolerability profile is an important focus of the clinical trials.

Ongoing Clinical Trials on Sotatercept

  • Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Denmark France Germany +7

  • Study on Sotatercept for Improving Heart Function in Patients with Pulmonary Arterial Hypertension

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Sotatercept for Children with Pulmonary Arterial Hypertension Receiving Standard Care

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Poland Spain

  • Study of gallium-68 FAPI imaging to assess blood vessel changes in patients with pulmonary arterial hypertension receiving sotatercept

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Tolerability of Sotatercept for Patients with Pulmonary Arterial Hypertension

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Italy The Netherlands Poland +1

  • Study on Sotatercept for Treating Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Spain +1

  • Study of Sotatercept for People with Pulmonary Arterial Hypertension

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Hungary Italy The Netherlands +2

  • Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality

    Not recruiting

    3 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Study on Sotatercept for Treating Pulmonary Hypertension in Adults with Heart Failure

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Poland Spain +1

  • Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark France +7

Glossary

  • Pulmonary Arterial Hypertension (PAH): A progressive disease characterized by high blood pressure in the arteries of the lungs, leading to right heart failure if left untreated.
  • 6-Minute Walk Distance (6MWD): A test that measures the distance a patient can walk in 6 minutes, used to assess exercise capacity and functional status in PAH and other conditions.
  • World Health Organization (WHO) Functional Class: A system for classifying the severity of symptoms in PAH patients, ranging from Class I (no limitation of physical activity) to Class IV (unable to perform any physical activity without symptoms).
  • N-terminal prohormone B-type natriuretic peptide (NT-proBNP): A biomarker in the blood that can indicate the severity of heart failure and is often used to monitor PAH progression.
  • Hemodynamics: The study of blood flow in the circulatory system. In PAH, key hemodynamic parameters include mean pulmonary artery pressure and pulmonary vascular resistance.
  • Right Heart Catheterization: A diagnostic procedure used to directly measure pressure in the pulmonary arteries and assess heart function in PAH patients.
  • REVEAL Lite 2 Risk Score: A scoring system used to assess the risk of mortality in PAH patients based on various clinical and laboratory parameters.
  • Subcutaneous Injection: A method of administering medication by injecting it into the tissue layer between the skin and muscle.
  • Dose-Limiting Toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dose or level of treatment in a clinical trial.
  • Anti-Drug Antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.

References